Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naïve and previous negative biopsy patients.
PI-RADS-Version-2
biopsy-naïve
combination of fusion and systematic biopsy
previous-negative biopsy
prostate cancer detection
uroNav
whole mount histopathology
Journal
Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
08
2022
accepted:
20
09
2022
entrez:
24
10
2022
pubmed:
25
10
2022
medline:
25
10
2022
Statut:
epublish
Résumé
Guidelines for previous negative biopsy (PNB) cohorts with a suspicion of prostate cancer (PCa) after positive multiparametric (mp) magnetic-resonance-imaging (MRI) often favour the fusion-guided targeted prostate-biopsy (TB) only approach for Prostate Imaging-Reporting and Data System (PI-RADS) ≥3 lesions. However, recommendations lack direct biopsy performance comparison within biopsy naïve (BN) vs. PNB patients and its prognostication of the whole mount pathology report (WMPR), respectively. We suppose, that the combination of TB and concomitant TRUS-systematic biopsy (SB) improves the PCa detection rate of PI-RADS 2, 3, 4 or 5 lesions and the International Society of Urological Pathology (ISUP)-grade predictability of the WMPR in BN- and PNB patients. Patients with suspicious mpMRI, elevated prostate-specific-antigen and/or abnormal digital rectal examination were included. All PI-RADS reports were intramurally reviewed for biopsy planning. We compared the PI-RADS score substratified TB, SB or combined approach (TB/SB) associated BN- and PNB-PCa detection rate. Furthermore, we assessed the ISUP-grade variability between biopsy cores and the WMPR. According to BN ( Despite csPCa is more frequently found in BN patients, the TB/SB method always detected a significantly higher number of csPCa within PI-RADS 3, 4 or 5 reports of our BN and PNB group. The TB/SB strategy predicts the ISUP-grade best in the total and BN cohort and in general shows the lowest upgrading rates, emphasizing its value not only in BN but also PNB patients.
Identifiants
pubmed: 36277287
doi: 10.3389/fsurg.2022.1013389
pmc: PMC9582510
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1013389Informations de copyright
© 2022 Mischinger, Schöllnast, Zurl, Geyer, Fischereder, Adelsmayr, Igrec, Fritz, Merdzo-Hörmann, Elstner, Schmid, Triebl, Trimmel, Reiter, Steiner, Rosenlechner, Seles, Pichler, Pichler, Riedl, Schöpfer-Schwab, Strobl, Hutterer, Zigeuner, Pummer, Augustin, Ahyai, Mannweiler, Fuchsjaeger and Talakic.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Urol. 2020 Oct;204(4):661-670
pubmed: 32552474
World J Urol. 2019 Mar;37(3):429-436
pubmed: 30003373
Cochrane Database Syst Rev. 2019 Apr 25;4:CD012663
pubmed: 31022301
Eur Urol Oncol. 2020 Apr;3(2):216-223
pubmed: 31239236
BJU Int. 2015 Apr;115(4):562-70
pubmed: 25252133
Eur Urol Oncol. 2020 Feb;3(1):112-118
pubmed: 31411973
BJU Int. 2019 Apr;123(4):612-617
pubmed: 30417504
Sci Rep. 2021 Mar 15;11(1):6048
pubmed: 33723287
Eur Urol. 2020 Mar;77(3):320-330
pubmed: 31771797
Eur Urol. 2015 Sep;68(3):438-50
pubmed: 25480312
J Urol. 2020 Jun;203(6):1085-1093
pubmed: 31609177
Eur Urol Oncol. 2020 Aug;3(4):474-480
pubmed: 31411978
J Urol. 2020 Apr;203(4):706-712
pubmed: 31642740
Eur Urol. 2019 Apr;75(4):570-578
pubmed: 30477981
Front Surg. 2020 Feb 28;7:7
pubmed: 32185180
Radiology. 2020 Jul;296(1):76-84
pubmed: 32315265
J Urol. 2019 Dec;202(6):1182-1187
pubmed: 31246548
Urology. 2015 Dec;86(6):1192-8
pubmed: 26335497
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
Transl Androl Urol. 2019 Dec;8(6):741-753
pubmed: 32038971
Can Urol Assoc J. 2022 Apr;16(4):E184-E196
pubmed: 35358414
Lancet Oncol. 2019 Jan;20(1):100-109
pubmed: 30470502
N Engl J Med. 2020 Mar 5;382(10):917-928
pubmed: 32130814
Ann Oncol. 2020 Sep;31(9):1119-1134
pubmed: 32593798
J Clin Oncol. 1999 Jan;17(1):168-72
pubmed: 10458230
BJU Int. 2018 Aug;122(2):211-218
pubmed: 29569320
J Urol. 2017 Sep;198(3):575-582
pubmed: 28373135
Int Urol Nephrol. 2021 Nov;53(11):2251-2259
pubmed: 34505227
Eur Urol Focus. 2019 Jul;5(4):592-599
pubmed: 29226826
J Urol. 2018 Oct;200(4):767-773
pubmed: 29733838
Eur Urol Focus. 2021 Jan;7(1):39-46
pubmed: 31296485
Scand J Urol. 2018 Jun;52(3):174-179
pubmed: 29463177
Cancer. 2016 Mar 15;122(6):884-92
pubmed: 26749141
Eur Urol. 2014 Jan;65(1):124-37
pubmed: 24207135
J Urol. 2016 Dec;196(6):1613-1618
pubmed: 27320841
N Engl J Med. 2017 Jul 13;377(2):132-142
pubmed: 28700844
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
World J Urol. 2019 Oct;37(10):2109-2117
pubmed: 30652213
JAMA. 2015 Jan 27;313(4):390-7
pubmed: 25626035
Eur Urol. 2016 Mar;69(3):428-35
pubmed: 26166626
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
J Urol. 2012 Dec;188(6):2152-2157
pubmed: 23083875
Eur Urol. 2013 Oct;64(4):544-52
pubmed: 23537686
Eur Urol Oncol. 2019 Nov;2(6):617-624
pubmed: 31519516
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566
Diagnostics (Basel). 2021 Jul 26;11(8):
pubmed: 34441270